Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
about
Establishment of a first‑line second‑line treatment model for human pulmonary adenocarcinomaPrognostic value of serum leptin in advanced lung adenocarcinoma patients with cisplatin/pemetrexed chemotherapyA phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer.Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized MedicineSorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.Differential regulation of autophagy and cell viability by ceramide species.Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLCSorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signalingPhase I study of pemetrexed with sorafenib in advanced solid tumors.How affordable are targeted therapies in non-small cell lung cancer?[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.Development and cross-validation of prognostic models to assess the treatment effect of cisplatin/pemetrexed chemotherapy in lung adenocarcinoma patients.Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients
P2860
Q28468342-1C07AFB5-393F-4726-B78A-99DB1CEF31AFQ33727749-68B10BE9-82ED-4067-BB96-0E1810D6F940Q33911180-E7388E39-6794-46AE-AC78-77A608396219Q34219452-32FA9224-D92D-4EE3-A419-5DCA90446E9AQ35113327-DB721105-0553-44D8-8FF5-B905111CBA79Q36214943-325DE0E9-009D-4B88-9BC0-16EB227B5C7FQ36624188-3DF53887-703B-4D07-B885-CEF3CE557B09Q36919811-9D450EBE-E85C-4133-A8E9-C8BD8FDF3348Q37520649-932690C7-F540-491D-8C46-58DA7F9C732FQ37832428-3B574D5E-0398-43F6-9238-EDB62243F154Q39888747-D644AD5A-8248-4C24-8678-BAF32CFD31B3Q54331093-FA4B5B88-7099-49EE-BECD-83E0C64BFBF4Q58748367-86717E5E-BA7D-4BF6-B571-3AEB9CBB543F
P2860
Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pemetrexed for the first-line ...... ic non-small cell lung cancer.
@ast
Pemetrexed for the first-line ...... ic non-small cell lung cancer.
@en
Pemetrexed for the first-line ...... ic non-small cell lung cancer.
@nl
type
label
Pemetrexed for the first-line ...... ic non-small cell lung cancer.
@ast
Pemetrexed for the first-line ...... ic non-small cell lung cancer.
@en
Pemetrexed for the first-line ...... ic non-small cell lung cancer.
@nl
prefLabel
Pemetrexed for the first-line ...... ic non-small cell lung cancer.
@ast
Pemetrexed for the first-line ...... ic non-small cell lung cancer.
@en
Pemetrexed for the first-line ...... ic non-small cell lung cancer.
@nl
P2093
P356
P1476
Pemetrexed for the first-line ...... ic non-small cell lung cancer.
@en
P2093
C Tudur Smith
J Greenhalgh
P356
10.3310/HTA14SUPPL1/07
P478
14 Suppl 1
P577
2010-05-01T00:00:00Z